×
Edesa Biotech Common Stock Net 2013-2024 | EDSA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Edesa Biotech common stock net from 2013 to 2024. Common stock net can be defined as the value of common equity ownership.
View More
Edesa Biotech Common Stock Net 2013-2024 | EDSA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Edesa Biotech common stock net from 2013 to 2024. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$174.8B
Vertex Pharmaceuticals (VRTX)
$133.1B
Gilead Sciences (GILD)
$120.2B
Bristol Myers Squibb (BMY)
$109.8B
Regeneron Pharmaceuticals (REGN)
$91B
CSL (CSLLY)
$90.5B
GSK (GSK)
$75.2B
Alnylam Pharmaceuticals (ALNY)
$35.8B
Argenex SE (ARGX)
$35.6B
BioNTech SE (BNTX)
$26.3B
Biogen (BIIB)
$25.2B
Illumina (ILMN)
$24B
BeiGene (BGNE)
$20B
Moderna (MRNA)
$18B
Incyte (INCY)
$16.1B
Genmab (GMAB)
$15.3B
Vaxcyte (PCVX)
$13.3B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$12.8B
Bio-Techne Corp (TECH)
$12.1B
Sarepta Therapeutics (SRPT)
$11.6B
Exelixis (EXEL)
$10.4B
Revolution Medicines (RVMD)
$10.2B
QIAGEN (QGEN)
$10B
Intra-Cellular Therapies (ITCI)
$9.7B
Exact Sciences (EXAS)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.8B
Repligen (RGEN)
$7.9B
Halozyme Therapeutics (HALO)
$7.8B